Retatrutide is an unapproved investigational triple agonist (GLP-1, GIP, glucagon receptors) not licensed by the MHRA, EMA, or FDA for routine clinical use
Bacteriostatic water contains 0.9% benzyl alcohol
Heart rate should be monitored at regular intervals consistent with usual clinical practice in patients taking semaglutide and patients should inform health care providers of palpitations or feelings of a racing heartbeat while at rest during semaglutide treatment
Phase 2 and Phase 3 trial data Major clinical trials: Phase 2 (24-week trial, 2008): 203 obese participants Three dose groups: 0.25mg, 0.5mg, 1.0mg daily Placebo-controlled, randomized Primary outcome: Weight loss percentage Phase 2 results: Key findings: Dose-dependent weight loss 1mg dose: Average 23 lbs lost (starting weight ~220 lbs) Best responders: 15-20% weight loss Comparable to semaglutide 2.4mg But higher dropout due to side effects Phase 3 trials (planned but never completed): Intended for FDA approval Halted due to cardiovascular concerns Increased heart rate 5-10 bpm average Blood pressure elevation 2-5 mmHg Risk-benefit ratio questioned Development suspended 2010 Long-term data (limited): 1-year extension studies showed sustained loss Weight plateau at 6-9 months Some regain if discontinued No controlled trials beyond 1 year Safety concerns prevented longer studies Compare to semaglutide trials and tirzepatide results
UPS 8.00 EUR brutto +44 (0) 7593 378943 Price: 52.00 EUR gross +44 (0) 7593 378943 Nucleon Nutrition AOD-9604 60 caps effective fat reduction and recovery support Many of us struggle with the problem of stubborn fat tissue that refuses to disappear despite diet and physical activity
Research demonstrates BPC-157's effectiveness for tendon healing in multiple studies
